A new oral drug developed by Swedish scientists increases metabolic activity directly in muscles, promoting fat burning without losing muscle mass, a common side effect of GLP-1 drugs used for diabetes and obesity[1][6]. In a clinical study, 48 healthy subjects and 25 patients with type 2 diabetes took 2.5 mg daily for 28 days, and the drug was well tolerated with only a mild and transient increase in heart rate[1]. This drug works by a different mechanism than GLP-1 agonists, so it could be combined with these drugs for a better effect on sugar level control and fat mass reduction[1]. Muscle mass is metabolically active and helps regulate blood glucose levels, so its preservation is important for long-term diabetes control[1]. While GLP-1 drugs often cause muscle loss of up to 15-40% of total weight loss, this new drug helps protect muscle[2]. There are other drugs under investigation, such as bimagrumab, which try to prevent muscle loss in the treatment of obesity and diabetes, but this new oral drug is a promising alternative with fewer side effects[1][4].